Intravascular stent and preparation method thereof

By designing the main support unit ring and auxiliary support unit ring of the self-expanding stent, combining the anticoagulant coating and drug tank, the endothelial dysfunction and late restenosis caused by the intravascular stent in the prior art are solved, and further achievement Good adherence and anticoagulant properties reduce the occurrence of long-term stenosis and thrombotic events.

CN118902708APending Publication Date: 2024-11-08JIANGSU NOWYON MEDICAL CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411072892.6
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-08-06
Publication Date
2024-11-08

AI Technical Summary

Technical Problem

After long-term implantation, existing intravascular stents can easily lead to endothelial dysfunction, chronic inflammatory response and coagulation abnormalities, resulting in late restenosis and thrombosis events. The drug coating cannot effectively prevent long-term stenosis after gradually eluting in the body. .

Method used

A self-expanding bracket is designed, including a main support unit ring and an auxiliary support unit ring. The main support unit ring is composed of a thick screw, and the auxiliary support unit ring is composed of a thin screw, combining an anticoagulation coating and a drug groove to enhance the bracket. The adherence and anticoagulant properties promote endothelialization and reduce long-term stenosis.

Benefits of technology

Through the structural design of the main support unit ring and auxiliary support unit ring, the stent provides better adherence and anticoagulant properties, reduces the risk of drug shedding, improves the drug targeted release ability, and reduces the blood vessel wall Stimulation reduces the occurrence of long-term stenosis and thrombotic events.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118902708A_ABST
    Figure CN118902708A_ABST
Patent Text Reader

Abstract

The invention relates to the technical field of medical instruments, in particular to an intravascular stent and a preparation method thereof. The invention provides an intravascular stent and a preparation method. The intravascular stent comprises a self-expanding stent, the self-expansion stent comprises a main support unit ring and an auxiliary support unit ring, the main support unit ring is a zigzag ring formed by a plurality of first screw rods, and the auxiliary support unit ring is a zigzag ring formed by a plurality of second screw rods; the width of the first lead screw is larger than that of the second lead screw. The technical problem that in the prior art, the effect of treating narrow blood vessels is poor is solved.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of medical devices, and in particular to an intravascular stent and a preparation method thereof. Background Art

[0002] Intravascular stent implantation is an effective means of treating vascular stenosis in the human body. Intravascular stents are mainly used in coronary arteries, cerebral blood vessels, peripheral blood vessels, veins and other specific blood vessels to open blood vessels, restore blood flow, and avoid serious consequences caused by ischemia. With the aging of the population and changes in lifestyle, the incidence of cardiovascular and cerebrovascular diseases continues to rise. Vascular stenosis and blockage caused by lesions such as atherosclerosis are becoming increasingly common, and there is a strong demand for intravascular stents. Specifically, when severe stenosis occurs in a blood vessel, it will greatly affect the normal flow of blood, leading to ischemia and hypoxia of organs and tissues. Drug treatment may not be able to completely solve the problem, and stents need to be inserted through interventional means to quickly restore vascular patency. In short, intravascular stents have an indispensable position in modern medicine, and their demand is also growing and developing.

[0003] In the early clinical application process, the commonly used stents were mainly made of biologically inert materials such as stainless steel, cobalt-chromium and nickel-titanium. They were hollowed-out tubular objects made by laser cutting. After the stent was implanted, the radial support force of the stent was used to open the blood vessels. However, such stents are prone to biocompatibility problems such as endothelial dysfunction, chronic inflammatory response, and abnormal coagulation function after long-term implantation in the human body as foreign bodies. As a result, drug-coated stents were later introduced, which wrapped a layer of drug coating on the outer surface of the original bare metal stent. The drugs mainly included rapamycin, paclitaxel and other anti-inflammatory and anti-proliferative drugs. The stents of this type of product inhibit smooth muscle cell proliferation through the drug coating on the outer surface of the stent. The target blood vessels do have a good patency rate in the early stage (6 to 12 months after surgery), but delayed restenosis, stent thrombosis events and even vascular occlusion in the medium and long term (12 to 36 months after surgery) are still inevitable. Because this type of stent product uses drugs to inhibit early restenosis, but as the drug is gradually eluted in the body, the drug concentration gradually decreases, and the excessive inflammatory stimulation of the stent material and the drug coating material on the target blood vessel continues to exist, so restenosis will still occur in the long term. Later, a stent with a slotted surface appeared. The outer part of the cobalt-chromium alloy stent was slotted using laser technology and filled with drugs wrapped in degradable materials. On the one hand, the stimulation of the drug coating on the target blood vessel is reduced, and on the other hand, the effect of unidirectional release of drugs to the arterial wall is achieved. However, the late cardiovascular complications of this product are not significantly different from those of non-slotted drug-eluting stents. The reason may be related to the delayed endothelialization of the stent itself. Endothelial cells cannot adhere to the metal stent, and the surface of the metal stent lacks a layer of "endothelial membrane", which leads to the deposition of other cell components in the blood such as macrophages, platelets and fibrin, inducing the formation of thrombus. Therefore, how to improve the long-term complications of the stent, reduce the stimulation of the stent on the blood vessel wall, increase the anticoagulant properties of the stent surface, promote endothelialization and reduce long-term stenosis is a problem that needs to be solved.

[0004] Publication No. CN103260549A disclosed a stent graft assembly on August 21, 2013, comprising a flexible material graft supported by a stent frame, the stent frame being configured to be deformable between an expanded state and a radially contracted state. The flexible material graft has a tubular shape, and when the graft is in an expanded, undeformed state, the graft is bent along the longitudinal axis of the tube. The stent graft assembly can be deformed into a state in which the graft is deformed into a straight tubular shape. This structure is not effective in treating stenotic blood vessels. Summary of the invention

[0005] The purpose of the present invention is to overcome the above-mentioned deficiencies of the prior art and to provide an intravascular stent and a preparation method thereof, which is intended to solve the technical problem that the prior art has poor effect in treating stenotic blood vessels.

[0006] To achieve the above-mentioned purpose, the present invention proposes an intravascular stent, including a self-expanding stent; the self-expanding stent includes a main support unit ring and an auxiliary support unit ring, the main support unit ring is a serrated ring composed of multiple first wire rods, and the auxiliary support unit ring is a serrated ring composed of multiple second wire rods; the first wire rod is wider than the second wire rod.

[0007] Preferably, the wire diameter of the main support unit ring is 0.04-0.12 mm; the wire diameter of the auxiliary support unit ring is 0.01-0.09 mm.

[0008] Preferably, the length ratio of the first screw rod to the second screw rod is 1.1:1-2:1.

[0009] Preferably, the number of the first screw rods provided in each of the main support unit rings is a, and the number of the second screw rods provided in each of the auxiliary support unit rings is b, wherein a:b=1:3~1:1.

[0010] Preferably, the angle formed between two adjacent first screw rods of each main support unit ring is 0°~90°; the angle formed between two adjacent second screw rods of each auxiliary support unit ring is 0°~80°.

[0011] Preferably, one auxiliary support unit ring is arranged between two adjacent main support unit rings; or a plurality of auxiliary support unit rings are arranged between two adjacent main support unit rings; and adjacent rings are connected via a connecting rod.

[0012] Preferably, a medicine groove is provided on the first screw rod, the width of the medicine groove is 0.02-0.10 mm, the depth is 0.005-0.10 mm, and the ratio of the length of the medicine groove to the first screw rod is 1:1-1:5.

[0013] Preferably, the width of the connecting rod is 0.04-0.12 mm; the ratio of the number of the first screw rods of a single main support unit ring to the number of the connecting rods arranged on one side thereof is 1:1-10:1.

[0014] Preferably, in the self-expanding state, the bending angles of the main support unit ring and the auxiliary support unit ring gradually decrease from the middle part of the bracket to the axial sides, the bending angle of the main support unit ring in the middle position is 35°~90°, and the bending angle of the auxiliary support unit ring in the middle position is 25°~80°; in the self-expanding state, the length of the screw rod of the main support unit ring and the auxiliary support unit ring gradually increases from the middle part of the bracket to the axial sides, and the ratio of the longest length to the shortest length is 1.5:1.

[0015] To achieve the above object, the present invention also provides a method for manufacturing an intravascular stent, wherein the method comprises the following steps: a. Select the pipe material; choose the hollow pipe with a wall thickness of 0.04 to 0.12 mm; b. Tube processing: Cut the selected tube using laser cutting technology, open a medicine groove on the outer surface of the stent, the length of the medicine groove is 5% to 60% of the total length of the stent rod, preferably 30%, and then polish it for use; c. Prepare a titanium dioxide stent; take 0.148g of ammonium fluorotitanate powder and add it to purified water to prepare 20ml of ammonium fluorotitanate solution, take 1.39g of boric acid powder and add it to purified water to prepare 20ml of boric acid solution, supersaturate the above ammonium fluorotitanate solution and boric acid solution in a water bath at 60°C for 12h, then mix the ammonium fluorotitanate solution and the boric acid solution, and hang the stent treated in step b vertically in the middle of the mixed solution, irradiate with UV light, select the UV light wavelength of 254nm, react in a water bath at 60°C for 2h, take out the stent, rinse it with purified water and dry it; d. Preparation of anticoagulant coated stents: Take 0.2g of poly D,L-lactide (PDLLA, weight average molecular weight range is 20,000-200,000), add it to 10ml of acetone at room temperature to prepare a uniform solution, then add 0.2g of rapamycin and mix evenly, accurately inject the solution into the drug groove of the stent, place the stent in a vacuum oven to dry, and remove the solvent to obtain the finished stent.

[0016] Compared with the prior art, the beneficial effects of the intravascular stent provided by the present invention are: 1. The stent includes a main support unit ring and an auxiliary support unit ring. The main support unit ring has a thick wire diameter and high hardness, and can provide radial support force; the auxiliary support unit ring has a thin wire diameter and low hardness, and can provide axial flexibility, so that the stent has better wall adhesion.

[0017] 2. The stent includes an anticoagulant coating and a drug part. The drug part is arranged in the drug groove of the main support unit ring. The drug groove structure reduces the risk of drug shedding during transportation. The stent coated with the anticoagulant coating further increases the viscosity of the drug, further reduces the drug loss during transportation, reduces the side effects of drug shedding, and improves the efficiency of drug treatment; the drug is loaded on the side of the stent that contacts the vascular tissue to improve the targeted drug release ability. The anticoagulant coating reduces the stimulation of the stent to the vascular wall, increases the anticoagulant properties of the stent surface, promotes endothelialization and reduces long-term stenosis.

[0018] 3. A drug groove is set on the main support unit to reduce the overall metal coverage of the stent, which is more conducive to tissue endothelialization.

[0019] 4. When the stent is released, the bending angles of the main support unit ring and the auxiliary support unit ring gradually decrease from the middle of the stent to the axial sides, and the length of the screw rods of the main support unit ring and the auxiliary support unit ring gradually increases from the middle of the stent to the axial sides, so that the middle of the stent has a greater support force and the two ends have a smaller support force. For clinical stenosis, most of the stenosis is more severe in the middle and less severe at the two ends, that is, the middle is more serious and the two ends are less severe. Therefore, the greater radial force in the middle of the stent is more conducive to the opening of blood vessels and the improvement of vascular lesions.

[0020] The features and advantages of the present invention will be described in detail through embodiments in conjunction with the accompanying drawings. BRIEF DESCRIPTION OF THE DRAWINGS

[0021] Figure 1 It is a schematic structural diagram of a self-expanding stent according to Embodiment 1 of the present invention.

[0022] Figure 2 It is a schematic structural diagram of a self-expanding stent according to a second embodiment of the present invention.

[0023] Figure 3 It is a schematic structural diagram of the self-expanding stent according to the first embodiment of the present invention entering a narrowed blood vessel.

[0024] Figure 4 It is a schematic diagram of a first structure of the connection between the main support unit ring and the auxiliary support unit ring in the first embodiment of the present invention.

[0025] Figure 5 It is a schematic diagram of a first structure of the connection between the main support unit ring and the auxiliary support unit ring in the first embodiment of the present invention.

[0026] Figure 6 It is a second structural schematic diagram of the connection between the main support unit ring and the auxiliary support unit ring in the first embodiment of the present invention.

[0027] Figure 7 This is a schematic diagram of a third structure of the connection between the main support unit ring and the auxiliary support unit ring in the first embodiment of the present invention.

[0028] Figure 8 It is a schematic cross-sectional view of the medicine groove of the third embodiment of the present invention.

[0029] in: 1-self-expanding stent; 11-main support unit ring; 111-first screw rod; 112-drug groove; 12-auxiliary support unit ring; 121-second screw rod; 3-connecting rod; 4-anticoagulant coating; 5-drug layer. DETAILED DESCRIPTION

[0030] In order to make the purpose, technical scheme and advantages of the present invention clearer, the present invention is further described in detail below through the accompanying drawings and embodiments. However, it should be understood that the specific embodiments described herein are only used to explain the present invention and are not intended to limit the scope of the present invention. In addition, in the following description, the description of known structures and technologies is omitted to avoid unnecessary confusion of the concept of the present invention.

[0031] In the description of the present invention, it should be noted that when an element is referred to as being "fixed to" or "disposed on" another element, it may be directly on the other element or indirectly on the other element. When an element is referred to as being "connected to" another element, it may be directly connected to the other element or indirectly connected to the other element.

[0032] In the description of the present invention, it should be noted that the terms "center", "length", "width", "thickness", "up", "down", "front", "back", "left", "right", "vertical", "horizontal", "top", "bottom", "inside", "outside" and the like indicate positions or positional relationships based on the positions or positional relationships shown in the accompanying drawings, or the positions or positional relationships in which the invention product is usually placed when in use, which are only for the convenience of describing the present invention and simplifying the description, rather than indicating or implying that the device or element referred to must have a specific orientation, be constructed and operated in a specific orientation, and therefore cannot be understood as limiting the present invention. In addition, the terms "first", "second", "third" and the like are only used to distinguish descriptions, and cannot be understood as indicating or implying relative importance. Therefore, the features defined as "first" and "second" may explicitly or implicitly include one or more of the features. In the description of the present invention, the meaning of "multiple" is two or more, unless otherwise clearly and specifically defined. The meaning of "several" is one or more, unless otherwise clearly and specifically defined.

[0033] In the description of the present invention, it is also necessary to explain that, unless otherwise clearly specified and limited, the terms "set", "install", "connect", and "connect" should be understood in a broad sense, for example, it can be a fixed connection, a detachable connection, or an integral connection; it can be a mechanical connection or an electrical connection; it can be a direct connection, or it can be indirectly connected through an intermediate medium, or it can be the internal communication of two elements. For ordinary technicians in this field, the specific meanings of the above terms in the present invention can be understood according to specific circumstances. Embodiment 1

[0034] See also Figure 1The embodiment of the present invention provides an intravascular stent, including a self-expanding stent, wherein the self-expanding stent 1 includes a main support unit ring 11 and an auxiliary support unit ring 12, wherein the main support unit ring 11 is a sawtooth ring composed of a plurality of first screw rods 111, and the main auxiliary support unit ring 12 is a sawtooth ring composed of a plurality of second screw rods 121. The width of the first screw rod 111 is larger than that of the second screw rod 121. The stent is divided into a self-expanding state and a conveying state. When not affected by external forces, the stent will automatically expand to Figure 1 State, at this time it is in the expanded state, in which the blood vessel support expansion can be achieved; when it is to be delivered, due to the relatively small diameter of the sheath, the stent after self-expansion cannot be placed in the sheath, so it needs to be compressed to be placed in the sheath, and as the sheath is delivered into the body, the compressed state can achieve the delivery of the stent. The stent can be self-expanding or balloon-expandable to achieve the above delivery and blood vessel support.

[0035] Furthermore, the main support unit rod 11 is thick and hard, and can provide radial support force; the auxiliary support unit rod 12 is thin and hard, and can provide axial flexibility, so that the stent has better wall adhesion, and the stent is more suitable for narrowed blood vessels and tortuous blood vessels in the human body, such as Figure 3 When the narrowing of the blood vessel occurs in the tortuous part, the stent with the main support unit rod 11 is used, which often has a large gap at the corner, poor wall adhesion, and even the main support rod may break the blood vessel, causing harm; when the auxiliary support unit ring 12 is added, the stent has better flexibility and wall adhesion, increases the contact area with the blood vessel, and is not easy to shift or break the blood vessel while opening the blood vessel.

[0036] Each unit ring of the stent is serrated, and the axial and circumferential expansion is more uniform, which can reduce the dogboning effect. At the same time, because each serrated screw is set at an angle, the forces on the outer circumference of the stent are not all tangential, so that the stent cannot rotate circumferentially.

[0037] See also Figure 4 In an optional embodiment, an auxiliary support unit ring 12 is disposed between two adjacent main support unit rings 11. That is to say, the main support unit rings 11 and the auxiliary support unit rings 12 appear alternately, one main support unit ring 11 is next to one auxiliary support unit ring 12, and the adjacent unit rings are connected by a connecting rod 3. The outermost side of the stent is generally provided with an auxiliary support unit ring 11, which generally has a developing mark and needs to be relatively softer and have better wall adhesion.

[0038] See also Figure 5In an optional embodiment, a plurality of auxiliary support unit rings 12 are arranged between two adjacent main support unit rings 11, and the adjacent rings are connected by a connecting rod 3. Preferably, there are two auxiliary support unit rings 12 arranged between the main support unit rings 11. In narrow blood vessels in curved parts, especially blood vessels with relatively large bending angles, in order to better fit the blood vessel wall, a plurality of auxiliary support unit rings 12 have better flexibility. The outermost side of the stent is generally provided with an auxiliary support unit ring 11, and the outermost side generally has a developing mark, which needs to be relatively softer and have better wall adhesion.

[0039] See also Figure 6 In an optional embodiment, a plurality of main support unit rings 11 are arranged between two adjacent auxiliary support unit rings 12, and the adjacent rings are connected by a connecting rod 3. Specifically, two main support unit rings 11 are preferred. This connection method is suitable when a stronger support force is required in a long straight narrow blood vessel. The outermost side of the stent is generally provided with an auxiliary support unit ring 11, which generally has a development mark and needs to be relatively softer and have better wall adhesion.

[0040] In an optional embodiment, Figure 4-6 The three distribution modes can appear in one stent to cope with the actual narrow blood vessels. That is, one auxiliary support unit ring 12 is arranged between two adjacent main support unit rings 11 in the stent, multiple auxiliary support unit rings 12 are arranged between two adjacent main support unit rings 11, and multiple main support unit rings 11 are arranged between two adjacent auxiliary support unit rings 12. All of them can appear in one stent.

[0041] Furthermore, the connecting rod 3 is mainly used to disperse stress. The connecting rod 3 can be straight or curved or axially inclined. The shape can be changed according to the application scenario to achieve the axial bending ability of the stent. The side of the connecting rod 3 facing the blood vessel wall is smooth to prevent scratching the blood vessel and causing inflammation. The connecting rod 3 can make the adjacent unit rings curved, making it easier to unfold and fit the blood vessel wall in the blood vessel. The function of the connecting rod is to connect the main support unit ring and the auxiliary support unit ring. The connecting rod is made into a curved or inclined shape or fewer connecting rods for the axial softness of the stent. The softer the stent is in the axial direction, the easier it is to adhere to the wall when the blood vessel is curved. When the stent is released in a tortuous blood vessel, the curved or inclined connecting rod can provide a certain tensile deformation, so that the stent has better wall adhesion.

[0042] See also Figure 4In an optional embodiment, the width of the connecting rod 3 is 0.04-0.12 mm, preferably 0.06 mm. The wire diameter of the main support unit ring 11 is 0.04-0.12 mm, preferably 0.06 mm; the wire diameter of the auxiliary support unit ring 12 is 0.01-0.09 mm, preferably 0.03 mm. It is the auxiliary support unit ring that improves the vascular wall adhesion function, so the connecting rod 3 is relatively short, and the connecting rod can be set to be relatively wide, preferably as wide as the main support unit ring. The ratio of the number of first screw rods 111 of a single main support unit ring 11 to the number of connecting rods 3 set on one side thereof is 1:1-10:1, preferably 2:1. The number of connecting rods can be set a little less, and the overall flexibility of the stent will be better, but generally not less than two, and the distribution should be as uniform as possible. The length ratio of the first screw rod 111 to the second screw rod 121 is 1.1:1-2:1, preferably 4:3. The number of the first screw rods 111 provided in each of the main support unit rings 11 is a, and the number of the second screw rods 121 provided in each of the auxiliary support unit rings 12 is b, wherein a:b=1:3~1:1, preferably 2:3.

[0043] Furthermore, the ratio of the main support unit ring 11 to the auxiliary support unit ring 12 is 1:1, and they appear alternately. There are 2n connecting rods between adjacent unit rings (where n is 1, 2, 3, 4, 5, 6), the number of first screw rods 111 set for each main support unit ring 11 is 8n (where n is 1, 2, 3, 4, 5, 6), and the number of second screw rods 121 set for each auxiliary support unit ring 12 is 12n (where n is 1, 2, 3, 4, 5, 6), and n is preferably 1. That is, there are two connecting rods, and 8 first screw rods 111 are set on the main support unit ring 11 connected on the left and right sides of the two connecting rods, and 12 second screw rods 121 are set on the auxiliary support unit ring 12, and the connecting rods 121 are evenly distributed circumferentially.

[0044] In an optional embodiment, the angle formed between two adjacent first screw rods 111 of each of the main support unit rings 11 is 0°~90°. The angle formed between two adjacent second screw rods 121 of each of the auxiliary support unit rings 12 is 0°~80°. The angles are all calculated using 0~90°. In a compressed state, the first screw rods 111 of each unit ring are close to each other, and all the first screw rods 111 can be parallel. In a compressed state, the second screw rods 121 of each unit ring are close to each other, and all the second screw rods 121 can be parallel. In this state, the angle formed between adjacent first screw rods 111 is 0°, and the angle formed between adjacent second screw rods 121 in this state is 0°. After release in the blood vessel, the angle between the adjacent first wire rods 111 and the adjacent second wire rods 121 in a single unit ring gradually increases, and the angle is the largest when released to the maximum position in the blood vessel. When released to the maximum position in the blood vessel, the angle between the adjacent first wire rods 111 is 35° to 90° (preferably 60°), and the angle between the adjacent second wire rods 121 is 25° to 80° (preferably 50°). Of course, if it is a self-expanding stent, the angle is the largest when it expands to the maximum state without external resistance in vitro.

[0045] The adjacent first screw rods 111 on the main support unit ring 11 are connected by a bent portion, which is excessively smooth and will not scratch the blood vessel wall. The adjacent second screw rods 121 on the auxiliary support unit ring 12 are connected by a bent portion, which is excessively smooth and will not scratch the blood vessel wall. In an optional embodiment, a developing device is provided on the stent, which is visible under X-ray irradiation. The developing device can be provided at both ends of the stent, or on the second screw rod, preferably on the second screw rod of the middle auxiliary support unit ring. Embodiment 2

[0046] For clinical stenosis, most of the stenosis is that the stenosis ratio in the middle part is larger, and the stenosis ratio at the two ends is smaller, that is, the middle part is more serious, and the stenosis at the two ends is second. Therefore, the larger radial force in the middle part of the stent is more conducive to the opening of the blood vessels and the improvement of vascular lesions. On the basis of the structure of embodiment 1 (or the basic structure of the intravascular stent is that the stent 1 includes a main support unit ring 11 and an auxiliary support unit ring 12, the main support unit ring 11 is a serrated ring composed of multiple first screw rods 111, and the auxiliary support unit ring 12 is a serrated ring composed of multiple second screw rods 121), the structure of the middle ring extending from the unit ring in the middle of the stent to both sides is improved, and the specific improvements are as follows: In an optional embodiment, in a compressed state, the first screw rods 111 of each unit ring are close to each other, and all the first screw rods 111 can be parallel. In a compressed state, the second screw rods 121 of each unit ring are close to each other, and all the second screw rods 121 can be parallel. In this state, the angle formed by the adjacent first screw rods 111 is 0°, and the angle formed by the adjacent second screw rods 121 is 0°. After release in the blood vessel. Figure 2 , in the expanded state in the blood vessel, the bending angles of the main support unit ring 11 and the auxiliary support unit ring 12 gradually decrease from the middle part of the stent to the axial sides, the bending angle of the main support unit ring 11 in the middle position is 35°~90°, preferably 60°, and the bending angle of the auxiliary support unit ring 12 in the middle position is 25°~80°, preferably 50°; in the expanded state in the blood vessel, the length of the wire rod of the main support unit ring 11 and the auxiliary support unit ring 12 gradually increases from the middle part of the stent to the axial sides, and the ratio of the longest length to the shortest length is 1.5:1. Therefore, the larger radial force in the middle part of the stent is more conducive to the opening of the blood vessel and the improvement of vascular lesions, and the density of the main support unit ring and the auxiliary support unit ring in the middle part of the stent is larger, and the metal coverage rate is larger, and the density of the main support unit ring and the auxiliary support unit ring at the two sides of the stent is smaller, and the metal coverage rate is smaller. Reduce the total volume of the stent in the body and reduce the occurrence of inflammation. The stent can be self-expanding or balloon-expandable to achieve the above delivery and vascular support.

[0047] See also Figure 2 In an optional embodiment, the outermost side of the stent is an auxiliary support unit ring 12, which is provided with a development mark, is soft and has better wall adhesion, and the two sides are arranged in a trumpet shape to prevent the stent from moving in the blood vessel. Embodiment 3

[0048] On the basis of the first and second embodiments, in order to increase the anti-coagulation property and drug carrying capacity of the stent surface, the following improvements are made to the stent.

[0049] See also Figure 7In an optional embodiment, a drug groove 112 is provided on the first screw rod 111, and the drug is accurately measured and filled into the drug groove, which reduces the risk of drug shedding during the delivery of the stent, improves the utilization rate of the drug, ensures the controllable release of the drug, and after the stent is released in the blood vessel, the drug is slowly and stably released in the blood vessel, thereby improving the safety and effectiveness of the stent during use. . The drug groove 112 is 0.02-0.10 mm wide and 0.005-0.10 mm deep. The ratio of the length of the drug groove 112 to the first screw rod 111 is 1:1-1:5, preferably 1:1.2 or 1:1.3. The ratio of its groove length to the total length of the stent rod is 5%-60% (excluding 60%), preferably 30%. The drug groove 112 can be a groove along the first screw rod 111, or a dot-shaped rib surface, or a special shape, or a micropore, which can be obtained by laser cutting or etching. The slot length here refers to the cumulative sum of the lengths of all the medicine slots in the entire stent along the length direction of the screw rod; the total length of the stent rod refers to the sum of the lengths of all the first screw rods and the second screw rods in the main support unit and the auxiliary support unit. For example, for a dot-shaped medicine slot, the origin is distributed along the circumference of the stent, not in the axial direction. When calculating, only the length of one dot along the length direction of the screw rod is calculated. If there is partial overlap, the overlapping part needs to be subtracted. For other shapes, refer to the calculation method of dots.

[0050] The role of the drug groove: delivery reduces the risk of drug shedding, and a lower drug dosage can achieve the same effect as similar (no groove) products, because the inner surface of the stent will not actually work and will be washed away by the blood as it degrades. If the stent contains degradable polylactic acid, the release is more stable. After implantation, the polylactic acid will release the drug during the degradation process.

[0051] In an optional embodiment, a developing wire can be set in the drug groove. The material of the developing wire is platinum tungsten, platinum, or gold wire, and is pressed into the groove by spinning. During the stent implantation process, the stent has a better development effect, which is convenient for the operator to perform the implantation surgery.

[0052] The stent is composed of a hollow tubular object or a curled hollow tubular object, which can be obtained by laser cutting and shaping of the tube, and the material is cobalt-chromium alloy, nickel-titanium alloy, iron-based magnesium alloy, degradable material, etc. After the outside of the stent is coated with an anticoagulant coating 4, a mixed solution with medicine is injected or sprayed in the drug groove 112, and the solvent is dried to remove the drug layer 5. Among them, the outer surface of the stent includes an anticoagulant coating, and the anticoagulant coating can be phosphorylcholine, which can be achieved by a dip coating process, or a titanium dioxide coating, which can be prepared by liquid phase deposition. Or a titanium dioxide coating-citric acid coating can be prepared by liquid phase deposition plus dip coating. The coating is coated on the surface of the stent to prevent the formation of thrombus and shorten the endothelialization time. And the stent coated with the anticoagulant coating has better viscosity to the drug in the drug groove, reducing the risk of drug falling off during delivery. The drug tank 112 stores drugs, and the drug portion includes drugs or a mixture of drugs and high molecular polymers. The drugs include drugs that inhibit cell proliferation, such as rapamycin (Rapamycn), paclitaxel (Taxol, Paclitaxel), vincristine (Vincristine), mitomycin (Mitomycin), etc.; or drugs that inhibit cell migration, such as c-proteinase inhibitors (C-Proteinase inhibitors), prolyl 3-hydroxylase inhibitors (Prolyl Hydroxylase inhibitors), halofuginone (halofuginone), etc. Embodiment 4

[0053] The method for manufacturing the stent of the above-mentioned embodiments 1-3 comprises the following steps: a. Select the pipe material; select a hollow pipe with a wall thickness of 0.04-0.12 mm (preferably 0.06), the material of the pipe is cobalt-chromium alloy, nickel-titanium alloy, iron-based magnesium alloy, degradable material, etc., and the material is preferably nickel-titanium pipe; b. Tube processing; the selected tube is cut into the required shape in Examples 1-3 by laser cutting technology, a medicine groove is opened on the outer surface of the stent, and the ratio of the length of the medicine groove to the total length of the stent rod is 5% to 60%, preferably 30%, and the product is put into standby after polishing process. The standby product is shaped, which can be a straight tube or a curled tube; (the treatment here can also be to first straighten the tube or the curled tube and then cut into the required shape in Examples 1-3 by laser cutting technology, and a medicine groove is opened on the outer surface of the stent, and the ratio of the length of the groove to the total length of the stent rod is 5% to 60%, preferably 30%, and the product is put into standby after polishing process) c. Prepare a titanium dioxide stent by liquid phase deposition; take 0.148g of ammonium fluorotitanate powder and add it to purified water to prepare 20ml of ammonium fluorotitanate solution, take 1.39g of boric acid powder and add it to purified water to prepare 20ml of boric acid solution, supersaturate the above ammonium fluorotitanate solution and boric acid solution in a water bath at 60°C for 12h, then mix the ammonium fluorotitanate solution and the boric acid solution, and hang the stent treated in step b vertically in the middle of the mixed solution, irradiate with UV light, select the UV light wavelength of 254nm, react in a water bath at 60°C for 2h, take out the stent, rinse it with purified water and dry it; Alternatively, the phosphorylcholine anticoagulant coating is applied by a dip coating process; Alternatively, the titanium dioxide coating-citric acid coating is prepared by liquid phase deposition plus dip coating.

[0054] d. Preparation of drug-eluting stents: Take 0.2 g of poly D,L-lactide with a weight average molecular weight range of 20,000-200,000, add it to 10 ml of acetone at room temperature to prepare a uniform solution, then add 0.2 g of rapamycin and mix evenly, accurately inject the solution into the drug groove of the stent, place the stent in a vacuum oven to dry, and remove the solvent to obtain the finished stent.

[0055] Among them, there are three different anticoagulant coatings in step c, including phosphorylcholine coating, titanium dioxide coating or titanium dioxide coating-citric acid coating, and the three different coating preparation methods are also different. In step d, the drug can be a drug that inhibits cell proliferation, such as one or more of rapamycin (Rapamycn), taxol (Taxol), vincristine (Vincristine), mitomycin (Mitomycin), Paclitaxel, etc.; or a drug that inhibits cell migration, such as c-proteinase inhibitors (C-Proteinase inhibitors), prolyl 3-hydroxylase inhibitors (Prolyl Hydroxylaseinhibitors), halofuginone, etc. One or more. The preparation method is to dissolve the drug in a solvent, or the drug and the degradable polymer are dissolved in a solvent respectively, and a mixed solution is made, and then injected or sprayed into the drug storage bin of the stent, and the solvent is dried to remove the drug layer.

[0056] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modification, equivalent substitution or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.

Claims

1. An intravascular stent, characterized in that: The bracket (1) comprises a main support unit ring (11) and an auxiliary support unit ring (12); the main support unit ring (11) is a sawtooth ring formed by a plurality of first screw rods (111); and the auxiliary support unit ring (12) is a sawtooth ring formed by a plurality of second screw rods (121); the first screw rods (111) are wider than the second screw rods (121).

2. An intravascular stent according to claim 1, characterized in that: The wire diameter of the main support unit ring (11) is 0.04-0.12 mm; the wire diameter of the auxiliary support unit ring (12) is 0.01-0.09 mm.

3. The intravascular stent according to claim 1, characterized in that: The length ratio of the first screw rod (111) to the second screw rod (121) is 1.1:1 to 2:

1.

4. The intravascular stent according to claim 1, characterized in that: The number of first screw rods (111) provided in each main support unit ring (11) is a, and the number of second screw rods (121) provided in each auxiliary support unit ring (12) is b, wherein a:b=1:3~1:

1.

5. The intravascular stent according to claim 1, characterized in that: The angle formed between two adjacent first screw rods (111) of each main support unit ring (11) is 0° to 90°; the angle formed between two adjacent second screw rods (121) of each auxiliary support unit ring (12) is 0° to 80°.

6. The intravascular stent according to claim 1, characterized in that: One auxiliary support unit ring (12) is arranged between two adjacent main support unit rings (11); or a plurality of auxiliary support unit rings (12) are arranged between two adjacent main support unit rings (11); and adjacent rings are connected via a connecting rod (3).

7. The intravascular stent according to claim 1, characterized in that: The first screw rod (111) is provided with a medicine groove (112), the medicine groove (112) has a width of 0.02 to 0.10 mm and a depth of 0.005 to 0.10 mm, and the ratio of the length of the medicine groove (112) to the first screw rod (111) is 1:1 to 1:

5.

8. The intravascular stent according to claim 6, characterized in that: The width of the connecting rod (3) is 0.04-0.12 mm; the ratio of the number of the first screw rods (111) of a single main support unit ring (11) to the number of the connecting rods (3) arranged on one side thereof is 1:1-10:

1.

9. The intravascular stent according to claim 1, characterized in that: In the self-expanding state, the bending angles of the main support unit ring (11) and the auxiliary support unit ring (12) gradually decrease from the middle of the stent to both axial sides; in the self-expanding state, the lengths of the screw rods of the main support unit ring (11) and the auxiliary support unit ring (12) gradually increase from the middle of the stent to both axial sides.

10. A method for manufacturing an intravascular stent, characterized in that: Manufacturing the intravascular stent according to any one of claims 1 to 9 comprises the following steps: a. Select the pipe material; choose the hollow pipe with a wall thickness of 0.04 to 0.12 mm; b. Tube processing: Cut the selected tube using laser cutting technology, open a medicine groove on the outer surface of the stent, the length of the medicine groove is 5% to 60% of the total length of the stent rod, preferably 30%, and then polish it for use; c. Prepare a titanium dioxide stent; take 0.148g of ammonium fluorotitanate powder and add it to purified water to prepare 20ml of ammonium fluorotitanate solution, take 1.39g of boric acid powder and add it to purified water to prepare 20ml of boric acid solution, supersaturate the above ammonium fluorotitanate solution and boric acid solution in a water bath at 60°C for 12h, then mix the ammonium fluorotitanate solution and the boric acid solution, and hang the stent treated in step b vertically in the middle of the mixed solution, irradiate with UV light, the UV light wavelength is selected to be 254nm, react in a water bath at 60°C for 2h, take out the stent, rinse with purified water and then dry; or apply a phosphorylcholine anticoagulant coating by a dip coating process; or prepare a titanium dioxide coating-citric acid coating by liquid phase deposition plus dip coating; d. Preparation of anticoagulant coated stents: Take 0.2 g of poly D,L-lactide with a weight average molecular weight range of 20,000-200,000, add it to 10 ml of acetone at room temperature to prepare a uniform solution, then add 0.2 g of rapamycin and mix evenly, accurately inject the solution into the drug groove of the stent, place the stent in a vacuum oven to dry, and remove the solvent to obtain the finished stent.